• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

No increase in mortality with paclitaxel-coated devices among patients with femoropopliteal disease

byNeel MistryandTeddy Guo
December 13, 2023
in Cardiology, Chronic Disease, Surgery
Reading Time: 2 mins read
Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]
Share on FacebookShare on Twitter

1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated analyses groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The safety of paclitaxel-coated devices for femoropopliteal disease has been well-studied; however, a 2018 meta-analysis raised concerns about increased mortality risk with paclitaxel. This meta-analysis aimed to provide updated insights on data from ten different trials comparing mortality rates between paclitaxel-coated and control (non-paclitaxel-coated) devices. The primary outcome was the effect of paclitaxel exposure on mortality, while key secondary outcomes were the impact of paclitaxel dose and baseline covariates. According to study results, there was no significant increase in mortality between the paclitaxel-coated and non-paclitaxel-coated devices. Although this study was well done, it was limited by variability in trial design and patient populations, affecting the validity of results.

Click to read the study in The Lancet

Relevant Reading: Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease

In-depth [meta-analysis]: Between 2005 and 2018, 10 trials were included comparing paclitaxel-coated versus control devices for femoropopliteal occlusive disease. Altogether, 2666 patients were included in the final analysis, with a median follow-up of 4.9 years. The primary outcome reported no significant increase in deaths associated with paclitaxel-coated devices (hazard ratio [HR] 1.14, 95% confidence interval [CI] 0.93-1.40). Similarly, the unadjusted HR for all-cause mortality comparing paclitaxel-coated and control-treated participants was 1.02 (95% CI 0.78-1.34), offering reassurance to patients, physicians, and regulators on their safety. Overall, findings from this study suggest that paclitaxel-coated devices do not pose an increased risk of mortality.

RELATED REPORTS

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

Paclitaxel-coated devices do not reduce rates of major amputations in chronic limb-threatening ischemia

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: claudicationfemoropopliteal diseaseinterventional radiologypaclitaxelpaclitaxel-coated devicePeripheral Arterial Diseaseperipheral vascular diseasevascular surgery
Previous Post

COVID virologic rebound may occur in patients treated with nirmatrelvir-ritonavir

Next Post

A low-inflammatory diet is associated with a lower incidence of diabetes

RelatedReports

Thoracic radiotherapy improves survival in small-cell lung cancer patients
Chronic Disease

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

April 15, 2026
Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]
Cardiology

Paclitaxel-coated devices do not reduce rates of major amputations in chronic limb-threatening ischemia

October 31, 2025
Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
Chronic Disease

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

July 24, 2025
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Chronic Disease

Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients

July 23, 2025
Next Post

A low-inflammatory diet is associated with a lower incidence of diabetes

The 2 Minute Medicine Podcast Episode 15

The 2 Minute Medicine Podcast Episode 30

Few older adolescents meet recommended levels of physical activity

Wellness Check: Exercise

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pairing cardiac magnetic resonance with electrocardiograms (ECGs) improved artificial intelligence (AI) assessments of cardiovascular diseases
  • Low-dose radiotherapy may be effective as a short-term therapeutic option in knee osteoarthritis
  • Physician edits to artificial intelligence (AI)-generated messages to patients were associated with different response time burdens
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.